The Effectiveness of Elbasir/Grazoprevir in Hepatitis C Patients with Stage 5 Chronic Kidney Disease (CKD)
DOI:
https://doi.org/10.24871/2522024302Keywords:
Hepatitis C, stage 5 CKD, effectiveness, elbasvir/grazoprevirAbstract
ABSTRACT
Introduction: Treatment of hepatitis C in end stage renal disease patients still a clinical challenge. Elbasvir/grazoprevir is a type of direct acting antiviral (DAA) drug used in treatment of Hepatitis C virus patients with renal disease. However, research on effectiveness of elbasvir/grazoprevir in hepatitis c virus patients with stage 5 chronic kidney disease (CKD) was limited. Therefore, this study aims to describe the effectiveness of elbasvir/grazoprevir on hepatitis C patients with stage 5 chronic kidney disease (CKD).
Method: This research using analytic observational design with cross-sectional study approach. The effectiveness of elbasvir/grazoprevir in hepatitis C patients with stage 5 chronic kidney disease (CKD) were evaluated the viral load, SVR12, and kidney function. Data were obtained from medical records of hepatitis C patients at Hepatology Outpatient Clinic dr. Saiful Anwar hospital from January 1st 2021 until December 31st 2022. Data analysis used the chi-square test, paired t test, and the Wilcoxon test with a significance level of p<0.05 and 95% confidence level.
Results: This study obtained 52 respondents. Most of the patients after treatment elbasvir/grazoprevir had an SVR12 value of 94.23%. Creatinine levels significant increase from 122±40 mg/dl to 133.05±36.12 mg/dl (p=0,032). Urea levels significantly different from 12±3 mg/dl to 12.18±3.56 mg/dl (p=0,446).
Conclusion: Elbasvir/grazoprevir was effective to treat hepatitis C patients with stage 5 CKD.
Keywords: Hepatitis C, stage 5 CKD, effectiveness, elbasvir/grazoprevir
References
REFERENCES
Jafri, S. M., & Gordon, S. C. Epidemiology of Hepatitis C. Clinical liver disease. 2018;12(5):140–142. https://doi.org/10.1002/cld.783
Muljono D. Epidemiology of Hepatitis B and C in Republic of Indonesia. Euroasian journal of hepato-gastroenterology. 2017;7(1):55–59. https://doi.org/10.5005/jp-journals-l0018-1212
Azmi, A. N., Tan, S. S., & Mohamed, R. Hepatitis C and kidney disease: An overview and approach to management. World journal of hepatology. 2015;7(1):78–92. https://doi.org/10.4254/wjh.v7.i1.78
Ko, S.Y., and Choe, W. H. Management of hepatitis C viral infection in chronic kidney disease patients on hemodialysis in the era of direct-acting antivirals. Clinical and Molecular Hepatology. 2018;24:351-357. https://doi.org/10.3350/cmh.2017.0063
Khan, M. U., Mahmoud, M. I., & Butt, A. A. Hepatitis c virus and chronic kidney disease. Expert review of gastroenterology & hepatology. 2020;14(7):579–590. https://doi.org/10.1080/17474124.2020.1776111
Bell, A. M., Wagner, J. L., Barber, K. E., & Stover, K. R. Elbasvir/Grazoprevir: A Review of the Latest Agent in the Fight against Hepatitis C. International journal of hepatology. 2016;3852126. https://doi.org/10.1155/2016/3852126
Jacobson, I. M., Poordad, F., Firpi-Morell, R., Everson, G. T., Verna, E. C., Bhanja, S., Hwang, P., Caro, L., Robertson, M., Charles, E. D., & Platt, H. Elbasvir/Grazoprevir in People With Hepatitis C Genotype 1 Infection and Child-Pugh Class B Cirrhosis: The C-SALT Study. Clinical and translational gastroenterology. 2019;10(4):e00007. https://doi.org/10.14309/ctg.0000000000000007
Papudesu, C., Kottilil, S., & Bagchi, S. Elbasvir/grazoprevir for treatment of chronic hepatitis C virus infection. Hepatology international. 2017;11(2):152–160. https://doi.org/10.1007/s12072-016-9761-2
Lin, C. P., Liang, P. C., Huang, C. I., Yeh, M. L., Hsu, P. Y., Hsu, C. T., Wei, Y. J., Liu, T. W., Hsieh, M. Y., Hou, N. J., Jang, T. Y., Lin, Y. H., Wang, C. W., Lin, Z. Y., Chen, S. C., Huang, C. F., Huang, J. F., Dai, C. Y., Chuang, W. L., & Yu, M. L. Concordance of SVR12, SVR24 and SVR durability in Taiwanese chronic hepatitis C patients with direct-acting antivirals. PloS one. 2021;16(2):e0245479. https://doi.org/10.1371/journal.pone.0245479
Zhu, Y., & Chen, S. Antiviral treatment of hepatitis C virus infection and factors affecting efficacy. World journal of gastroenterology. 2013;19(47):8963–8973. https://doi.org/10.3748/wjg.v19.i47.8963
Chuang, W. L., & Yu, M. L. Host factors determining the efficacy of hepatitis C treatment. Journal of gastroenterology. 2013;48(1):22–30. https://doi.org/10.1007/s00535-012-0669-x
Choi, D. T., Puenpatom, A., Yu, X., Erickson, K. F., Kanwal, F., El-Serag, H. B., & Kramer, J. R. Effectiveness of Elbasvir/Grazoprevir in patients with hepatitis C virus genotype 1 infection and chronic kidney disease in the United States veterans population. Antiviral research. 2020;174:104698. https://doi.org/10.1016/j.antiviral.2019.104698
Chen, J., Li, Y., Li, G., & Lei, P. Elbasvir/grazoprevir treatment in an HCV-infected peritoneal dialysis patient. Renal failure. 2020;42(1):377–380. https://doi.org/10.1080/0886022X.2020.1753073
Atsukawa, M., Tsubota, A., Toyoda, H., Takaguchi, K., Kondo, C., Okubo, T., Hiraoka, et al. Efficacy and safety of elbasvir/grazoprevir for Japanese patients with genotype 1b chronic hepatitis C complicated by chronic kidney disease, including those undergoing hemodialysis: A post hoc analysis of a multicenter study. Journal of gastroenterology and hepatology. 2019;34(2):364–369. https://doi.org/10.1111/jgh.14447
Downloads
Published
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:
a. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
b. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
c. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
